[Thymectomy in myasthenia gravis].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000359:Aftercare; D000906:Antibodies; D000917:Antibody Formation; D001323:Autoantibodies / Q000276:immunology; D002951:Citrates / Q000276:immunology; D019343:Citric Acid; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000628:therapy*; D009469:Neuromuscular Junction / Q000503:physiopathology; D010956:Plasmapheresis; D011950:Receptors, Cholinergic / Q000276:immunology; D012121:Respiration, Artificial; D013601:T-Lymphocytes / Q000276:immunology; D013934:Thymectomy; D013945:Thymoma / Q000000981:diagnostic imaging; D013952:Thymus Hyperplasia / Q000150:complications; D014057:Tomography, X-Ray Computed
D000305:Adrenal Cortex Hormones; D000906:Antibodies; D001323:Autoantibodies; D002951:Citrates; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D019343:Citric Acid
Thymektomie bei Myasthenia gravis.